Research Paper Volume 15, Issue 11 pp 4963—4985
FDX1 serves as a prognostic biomarker and promotes glioma progression by regulating the immune response
Figure 3. Correlation of FDX1 with clinical characteristics. (A) Clinical characteristics in high- and low-FDX1 expression groups. (B–U) Stratified analysis of correlation of FDX1 with prognosis in different groups: age (> 41 vs. ≤41), gender (male vs. female), WHO stage (II, III, and IV), histology (LGG vs. GBM), tumor type (primary, recurrent, and secondary), 1p19q codeletion status (non-codeletion vs. codeletion), IDH mutation status (wildtype vs. mutant), and receipt of radiotherapy and chemotherapy (yes vs. no).